Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)

Key Inclusion Criteria \[Stage 1 and Stage 2\]: - Presence of an active choroidal neovascularization (CNV) lesion secondary to age-related macular degeneration (AMD); - Best corrected visual acuity (BCVA) between 80 and 35 letters (20/25 to 20/200 Snellen equivalent) in the study eye; - BCVA greater than 20 letters (approximately 20/400 Snellen equivalent) in the non-study eye; - Media clarity and pupillary dilation in the study eye sufficient for all planned study procedures; - Capable of giving signed willing to sign a consent form, which includes compliance with the requirements and restrictions listed in the willing to sign a consent form form (ICF) and in this protocol; - Other protocol-specified inclusion criteria may apply. \[Stage 1\]: - Greater than or equal to 3 and less than or equal to 6 prior treatments of an ocular anti-VEGF medication within the 8 months prior to Screening in the study eye, with demonstrated anatomic response, as assessed by the Investigator. \[Stage 2\]: - Treatment-naïve, or diagnosis of exudative neovascular age-related macular degeneration (nAMD) in the study eye. Key Exclusion Criteria \[Stage 1 and Stage 2\]: - History or current ocular disease in the study eye other than nAMD, that, might require medical or surgical intervention during the study; - Structural damage to the macula that is likely to preclude improvement in visual acuity in the study eye after resolution of the nAMD; - Any active intraocular or periocular infection or active intraocular inflammation; - Treatment with ocular anti-VEGF product in the study eye within 28 days before Week 1 \[Stage 1\] or within 56 days before Screening \[Stage 2\]. - Uncontrolled glaucoma in the study eye; - Uncontrolled blood pressure; - Females of child-bearing potential who are pregnant, intending to become pregnant, nursing, or who are not willing to use an acceptable form of contraception for the duration of the study; - Other protocol-specified exclusion criteria may apply. Always talk to your doctor about whether this trial is right for you.